Goal: Discuss the prognosis of pituitary adenomas considering their clinical consequences and resulting systemic changes, in addition to possible therapeutic measures for management. Method: Literature review carried out from October to November 2022, through searches in the Scielo and Pubmed databases with the descriptors "pituitary adenoma", "symptoms", "treatment" and "diagnosis". 2925 articles were found and, after the inclusion criteria, 13 studies were selected. Review: Pituitary adenoma (HA) is the second most common intracranial tumor in the population. HAs can be asymptomatic, oligosymptomatic or cause clinical repercussions for the patient, ranging from visual disturbances to infertility. In this context, the diagnosis of HAs can be complex and must be performed by interdisciplinary professionals, with magnetic resonance imaging being the gold standard exam for imaging diagnosis. Final Considerations: There are variants regarding the tumorextension, pace of evolution and degree of impact on surrounding structures -that must be taken into account in order to shape an individualized and effective planning for each patient.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.